Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 BIIB059 in active systemic lupus erythematosus
NL-OMON49909Phase 3Recruiting
- Sponsor
- Biogen
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of litifilimab in systemic lupus erythematosus (SLE) (3 arms), sponsored by Biogen. Primary endpoint: SRI-4 response at Week 52. Started Jun 2022; status: recruiting.
02
Drugs
litifilimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON49909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49909.